Search results for "Immune Regulation"

showing 10 items of 21 documents

Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis

2018

Background & Aims The CYLD lysine 63 deubiquitinase gene (CYLD) encodes tumor suppressor protein that is mutated in familial cylindromatosus, and variants have been associated with Crohn disease (CD). Splice forms of CYLD that lack exons 7 and 8 regulate transcription factors and functions of immune cells. We examined the expression of splice forms of CYLD in colon tissues from patients with CD and their effects in mice. Methods We performed immunohistochemical analyses of colon tissues from patients with untreated CD and patients without inflammatory bowel diseases (controls). We obtained mice that expressed splice forms of CYLD (sCYLD mice) without or with SMAD7 (sCYLD/SMAD7 mice) from tr…

0301 basic medicineTranscription FactorBiopsyInbred C57BLTransgenicImmune RegulationSettore MED/12MiceRandom Allocation0302 clinical medicineCrohn DiseaseReference ValuesNeedleIntestinal Mucosaintegumentary systemChemistryBiopsy NeedleGastroenterologyT helper cellFlow CytometryPost-translational ModificationImmunohistochemistryDeubiquitinating Enzyme CYLDCysteine Endopeptidasesmedicine.anatomical_structure030211 gastroenterology & hepatologyTumor necrosis factor alphaSignal TransductionGenetically modified mouseRegulatory T cellTransgeneMice TransgenicSmad7 ProteinTransforming Growth Factor beta103 medical and health sciencesImmune systemmedicineAnimalsHumansCytokine SignalingHepatologyAnimalHEK 293 cellsUbiquitinationMolecular biologyMice Inbred C57BLDisease Models Animal030104 developmental biologyDisease ModelsCytokine Signaling; Immune Regulation; Post-translational Modification; Transcription Factor; Biopsy Needle; Crohn Disease; Cysteine Endopeptidases; Deubiquitinating Enzyme CYLD; Disease Models Animal; Flow Cytometry; Immunohistochemistry; Intestinal Mucosa; Mice Inbred C57BL; Mice Transgenic; Random Allocation; Reference Values; Signal Transduction; Smad7 Protein; Transforming Growth Factor beta1; UbiquitinationTransforming growth factorGastroenterology
researchProduct

Cyclic AMP Represents a Crucial Component of Treg Cell-Mediated Immune Regulation

2016

T regulatory (Treg) cells are one of the key players in the immune tolerance network, and a plethora of manuscripts have described their development and function in the course of the last two decades. Nevertheless, it is still a matter of debate as to which mechanisms and agents are employed by Treg cells, providing the basis of their suppressive potency. One of the important candidates is cyclic AMP (cAMP), which is long known as a potent suppressor at least of T cell activation and function. While this suppressive function by itself is widely accepted, the source and the mechanism of action of cAMP are less clear, and a multitude of seemingly contradictory data allow for, in principle, tw…

0301 basic medicinelcsh:Immunologic diseases. AllergyFOXP3Mini ReviewT cellImmunologyimmune tolerance networkAdenylate kinaseBiologyregulatory T cellsImmune tolerance03 medical and health sciencesmedicineImmunology and Allergycyclic AMPReceptorEffectorimmune regulationFOXP3suppressionAdenosineCell biology030104 developmental biologymedicine.anatomical_structureadenosineImmunologylcsh:RC581-607Intracellularmedicine.drugFrontiers in Immunology
researchProduct

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells

2015

Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by imbalanced immune regulatory networks, and MS patient-derived T effector cells are inefficiently suppressed through regulatory T cells (Treg), a phenomenon known as Treg resistance. In the current study we investigated T cell function in MS patients before and after interferon-beta therapy. We compared cytokine profile, responsiveness for Treg-mediated suppression ex vivo and evaluated reactivity of T cells in vivo using a humanized mouse model. We found that CD4+ and CD8+ T cells of therapy-naive MS patients were resistant to Treg-mediated suppression. Treg resistance is associated with an augmented IL-6 product…

AdultAdolescentdiagnosisReceptor expressionT cellchemical and pharmacologic phenomenaMice SCIDAntibodies Monoclonal Humanizedmultiple sclerosisT-Lymphocytes RegulatoryCatalysisArticleInorganic ChemistryTCIRG1lcsh:ChemistryInterleukin 21Young AdultImmune systemCytotoxic T cellMedicineAnimalsHumansIL-2 receptorPhysical and Theoretical ChemistryMolecular BiologyT effector cellslcsh:QH301-705.5SpectroscopyImmunosuppression TherapyInflammationtherapybusiness.industryOrganic Chemistryimmune regulationGeneral MedicineInterferon-betaMiddle AgedReceptors Interleukin-6Computer Science ApplicationsTregmedicine.anatomical_structureAnimals Newbornlcsh:Biology (General)lcsh:QD1-999ImmunologyLeukocytes MononuclearbusinessCD8International Journal of Molecular Sciences
researchProduct

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With…

2012

Purpose This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Patients and Methods Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m2 intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day …

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation AutologousGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleSettore MED/01 - Statistica MedicaBortezomib03 medical and health sciences0302 clinical medicineRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationSurvival rateMultiple myelomaDexamethasoneAgedBortezomibbusiness.industryHazard ratioTranslational research Immune Regulation [ONCOL 3]Middle Agedmedicine.diseaseBoronic AcidsThalidomide3. Good healthSurgeryThalidomideTransplantationTreatment OutcomeOncologyPyrazines030220 oncology & carcinogenesisFemaleMultiple MyelomabusinessStem Cell Transplantation030215 immunologymedicine.drugJournal of Clinical Oncology
researchProduct

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autogra…

2011

Contains fulltext : 95663.pdf (Publisher’s version ) (Closed access) We present results of a phase 3 randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first- or second-line treatment. The primary objective was to demonstrate that autografting improves the 5-year event-free survival (EFS) from 30% to 50%. There were 223 enrolled patients, 72% men and 28% women, 83% after first and 17% after second-line treatment. Binet stages were progressive A 13%, B 67%, C 20%; at randomization, 59% were in complete remission, and 41% in less than complete remission. Patients were randomized between autografting (n = 112) and observation (n = …

AdultMalemedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyHematopoietic stem cell transplantationTransplantation AutologousBiochemistryGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurvival rateAgedbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationTranslational research Immune Regulation [ONCOL 3]Cell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineEuropeSurvival RateTransplantationTreatment OutcomeAlemtuzumabFemalebusinessmedicine.drug
researchProduct

Prostaglandin D2 regulates joint inflammation and destruction in murine collagen-induced arthritis.

2012

Item does not contain fulltext OBJECTIVE: Prostaglandin D2 (PGD2) may exert proinflammatory or antiinflammatory effects in different biologic systems. Although this prostanoid and the enzymes responsible for its synthesis are up-regulated by interleukin-1beta (IL-1beta) in human chondrocytes in vitro, the role of PGD2 in arthritis remains unclear. This study was undertaken to investigate the role of PGD2 in the inflammatory response and in joint destruction during the development of collagen-induced arthritis (CIA) in mice. METHODS: PGD2 and cytokine levels in mice with CIA were determined by enzyme-linked immunosorbent assay. Expression of hematopoietic PGD synthase (h-PGDS), lipocalin-typ…

Agonistmusculoskeletal diseasesmedicine.medical_specialtyIndolesmedicine.drug_classmedicine.medical_treatmentChemokine CXCL1ImmunologyInterleukin-1betaReceptors ProstaglandinArthritisInflammationProinflammatory cytokinechemistry.chemical_compoundMiceRheumatologyBone MarrowInternal medicinemedicineImmunology and AllergyAnimalsPharmacology (medical)Receptors ImmunologicReceptorintegumentary systembusiness.industryProstaglandin D2Hydantoinsmedicine.diseaseArthritis ExperimentalLipocalinsHindlimbInterleukin-10Up-RegulationIntramolecular OxidoreductasesInterleukin 10CytokineEndocrinologychemistryMice Inbred DBACytokinesJointslipids (amino acids peptides and proteins)Prostaglandin D2Immune Regulation Auto-immunity transplantation and immunotherapy [NCMLS 2]medicine.symptombusiness
researchProduct

Do Tr1 cells play a role in immunotherapy?

1999

AllergyVenomsmedicine.medical_treatmentImmunologyImmune regulationGeneral MedicineImmunotherapyBiologyAllergensTh1 Cellsmedicine.diseaseInterleukin 10CytokineImmune systemTh2 CellsDesensitization ImmunologicInsect venom allergyImmunologymedicineHypersensitivityImmunology and AllergyHumansInternational archives of allergy and immunology
researchProduct

The expression of CD68 in human umbilical cord mesenchymal stem cells: new evidences of presence in non-myeloid cell types.

2009

Since their first identification in bone marrow [2],MSC have attracted much attention for thei r potential todifferentiate towards several mature tissues. The efforts ofthe researchers aimed in finding new tissues, whichshould provide adequate cell numbers for regenerativemedicine applications (and between them, extraembryonicsources as umbilical cord and amniotic membrane, arebeing viewed with extreme interest).

Cell typeSettore BIO/16 - Anatomia UmanaImmunologyMesenchymal stem cellAntigens Differentiation MyelomonocyticMesenchymal Stem CellsGeneral MedicinePlacenta cord bankingBiologyUmbilical cordCord liningUmbilical Cordmedicine.anatomical_structureAntigens CDCell Line TumorCancer researchmedicineHumansMyeloid CellsStem cellCD68 mesenchymal stem cells umbilical cord immune regulation stem cell markersStem cell transplantation for articular cartilage repairAdult stem cellScandinavian journal of immunology
researchProduct

Discrete Time Versus Continuous Time Approach to the Autoimmune Response

1989

A discrete time model for the immune regulation recently proposed by Weisbuch and Atlan is extended to continuous coupling coefficients as well as to continuous concentration rates in continuous time. It is shown that depending on the choice of the network parameters typical immune responses can be observed.

Coupling (electronics)PhysicsDiscrete time and continuous timeImmune networkImmune regulationbiochemical phenomena metabolism and nutritionTopologyCoupling coefficient of resonators
researchProduct

Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis

2010

Autoreactive CD4+ T lymphocytes play a vital role in the pathogenesis of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Since the discovery of T helper 17 cells, there is an ongoing debate whether T helper 1, T helper 17 or both subtypes of T lymphocytes are important for the initiation of autoimmune neuroinflammation. We examined peripheral blood CD4+ cells from patients with active and stable relapsing-remitting multiple sclerosis, and used mice with conditional deletion or over-expression of the transforming growth factor-beta inhibitor Smad7, to delineate the role of Smad7 in T cell differentiation and autoimmune neuroinflammation. We found that Smad…

Encephalomyelitis Autoimmune ExperimentalMultiple SclerosisT helper 1Regulatory T cellT cellMolecular Sequence DataMice TransgenicBiologySmad7 ProteinMiceInterleukin 21medicineAnimalsHumansCytotoxic T cellAmino Acid SequenceIL-2 receptorAntigen-presenting cellMice Knockoutintegumentary systemEAEimmune regulationCD28Original ArticlesTh1 CellsNatural killer T cellMice Inbred C57BLmedicine.anatomical_structureT cell responsesImmunologyNeurology (clinical)Brain
researchProduct